<DOC>
	<DOCNO>NCT00271583</DOCNO>
	<brief_summary>Objective : To compare efficacy , safety tolerance 50 mg dose new antiprogestin , CDB-2914 0.75 mg bid dose levonorgestrel emergency contraception Design : Multicenter , randomize , double blind Phase II study compare 50 mg dose CDB-2914 0.75 mg bid dose levonorgestrel emergency contraception Subjects randomize receive one-time treatment either one dose 50 mg CDB-2914 ( follow 12 hour later placebo ) 2 dos 0.75 mg levonorgestrel follow-up visit 5-7 day expect onset menses another visit 12-14 day expect onset menses ( need ) The primary aim evaluate efficacy CDB-2914 use subject emergency postcoital contraceptive comparison group subject receive levonorgestrel .</brief_summary>
	<brief_title>Efficacy Trial CDB 2914 Emergency Contraception</brief_title>
	<detailed_description>Objective : To compare efficacy , safety tolerance 50 mg dose new antiprogestin , CDB-2914 0.75 mg bid dose levonorgestrel emergency contraception Design : Multicenter , randomize , double blind Phase II study compare 50 mg dose CDB-2914 0.75 mg bid dose levonorgestrel emergency contraception Duration : A one-time treatment either CDB-2914 levonorgestrel follow-up visit 5-7 day expect onset menses another visit 12-14 day expect onset menses ( need ) Treatment : A one-time treatment one following : - Two dos 0.75 mg levonorgestrel take 12 hour apart - One dose 50 mg CDB-2914 second placebo dose take 12 hour later Study Sites : Multicenter study United States Subjects : Women reproductive age ( least 18 year ) risk pregnancy within 72 hour unprotected coitus Sample Size : Approximately 811 woman enrol treatment group obtain 1540 evaluable subject Outcome Evaluations Primary : To evaluate efficacy CDB-2914 use subject emergency postcoital contraceptive comparison group subject receive levonorgestrel . Secondary : To compare tolerability ( measure vomit nausea ) CDB-2914 used subject emergency postcoital contraceptive group subject receive levonorgestrel . Safety/Other : To assess frequency intensity adverse event effect menstrual cycle subject administer CDB-2914 comparison subject give levonorgestrel .</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>Menstruating woman least 18 year old ; Give voluntary , write informed consent , agree observe study requirement ; Request emergency contraception within 72 hour ( 3 day ) unprotected coitus , define lack contraceptive use , condom breakage ( include condom lubricate spermicide ) barrier contraceptive method failure ; Reports act unprotected coitus current cycle within 72 hour prior enrollment ; Willing abstain act unprotected intercourse cycle ; History regular menstrual cycle ( mean length 2442 day intraindividual variation Â±5 day ) ; At least one normal menstrual cycle ( 2 menses ) post delivery abortion ; If subject recently discontinue hormonal contraception , one normal menstrual cycle ( 2 menses ) must complete entry study For woman recent history Depo Provera use , recent injection must least 3 month study entry subject must least one normal menstrual cycle ( 2 menses ) ; Available followup least next four week . Currently pregnant ( positive highsensitivity urine pregnancy test ) ; pregnant breastfeeding within past two month ; use hormonal method contraception current previous two cycle ; current user IUD ; tubal ligation ; partner history vasectomy ; unsure date last menstrual period ( +3 day ) ; irregular menstrual cycle define inclusion criterion ; nausea vomit within previous two week ; impair hypothalamicpituitaryadrenal reserve oral glucocorticoid replacement therapy last year . Subjects currently enrol investigational trial reenrolled study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>emergency contraception</keyword>
	<keyword>antiprogestin</keyword>
</DOC>